Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| LTZ Therapeutics | 2026 | Venture - Series Unknown | $40.0M | San Francisco |
| Cabaletta Bio | 2026 | Post-IPO Equity | Undisclosed | Philadelphia |
| Remedium Bio | 2026 | Venture - Series Unknown | Undisclosed | Needham |
| Incyclix Bio | 2026 | Series B | Undisclosed | Durham |
| Iterative Health | 2026 | Series C | Undisclosed | Cambridge |
| Crossbow Therapeutics | 2026 | Series B | $77.0M | Cambridge |
| Trogenix | 2025 | Series A | $94.1M | Edinburgh |
| Dualitas Therapeutics | 2025 | Series A | $65.0M | San Francisco |
| Alchemab Therapeutics | 2025 | Series A | $32.0M | London |
| Syndeio Biosciences | 2025 | Venture - Series Unknown | $90.0M | Indianapolis |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | LTZ Therapeutics | Venture - Series Unknown | $40.0M | San Francisco, United States |
| 2 | Cabaletta Bio | Post-IPO Equity | Undisclosed | Philadelphia, United States |
| 3 | Remedium Bio | Venture - Series Unknown | Undisclosed | Needham, United States |
| 4 | Incyclix Bio | Series B | Undisclosed | Durham, United States |
| 5 | Iterative Health | Series C | Undisclosed | Cambridge, United States |
| 6 | Crossbow Therapeutics | Series B | $77.0M | Cambridge, United States |
| 7 | Trogenix | Series A | $94.1M | Edinburgh, United Kingdom |
| 8 | Dualitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 9 | Alchemab Therapeutics | Series A | $32.0M | London, United Kingdom |
| 10 | Syndeio Biosciences | Venture - Series Unknown | $90.0M | Indianapolis, United States |
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Remedium Bio is a gene therapy company focused on the development of highly innovative treatments for a broad range of diseases.
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Iterative Health develops technology that can benefit patients anywhere, regardless of socioeconomic or geographic barriers.
Crossbow Therapeutics is a biotech company that develops targeted therapies to address cancer antigens.
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.
Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
Persist AI is a biotechnology company that builds long-acting microsphere formulations.
Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
TRIMTECH Therapeutics treats inflammatory and persistent CNS conditions by focusing on the elimination of harmful proteins.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Revisto is a pioneer AI-powered technology that simplifies the medical, legal, and regulatory review process for pharmaceutical marketing.
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
Amprion is a biotech company that focuses on the diagnosis for brain diseases.
Basys.ai automates the process of prior authorization and utilization management for health plans/payers using an AI-based platform.
NanoSyrinx is a discovery stage biotechnology company based at the University of Warwick's Medical School.
Superluminal Medicines is a generative biological and chemical company that innovates drug discovery and development processes.
OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.
RetiSpec is a medical imaging startup developing an eye scanner for early detection of Alzheimer's Disease pathology.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Eli Lilly has invested in 110 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Eli Lilly's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 17 different industry categories.
Among tracked funding rounds, Superluminal Medicines received $120.0M in a Series A round. Eli Lilly's total known invested capital is $4.1B.
Eli Lilly's average investment size is $49.3M across its portfolio of 110 companies.
Recent Eli Lilly portfolio additions include LTZ Therapeutics, Cabaletta Bio, Remedium Bio, Incyclix Bio, Iterative Health. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors